In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Medtronic (NYSE: MDT). The company’s shares closed yesterday at $90.03, close to its 52-week high of $91.50.
According to TipRanks.com, Lichtman is ranked 0 out of 5 stars with an average return of -4.3% and a 52.0% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $96.58, which is a 7.3% upside from current levels. In a report issued on August 13, Needham also upgraded the stock to Buy with a $119 price target.
.
See today’s analyst top recommended stocks >>
Medtronic’s market cap is currently $121.9B and has a P/E ratio of 39.84. The company has a Price to Book ratio of 2.40.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
